Status: Not yet recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.
Participants needed: 100
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Atavistik Bio, IncUpdated: Jun 8, 2026
Eligibility criteria
Ability to provide informed consent prior to any study-specific procedures [+5]
Clinically significant abnormalities of glucose metabolism including diagnosed T... [+7]